Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2012-05-11 Regulatory Filings
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans, such as equity compensation plans. It includes details about the number of shares registered, the plan under which they are issued, and references to other SEC filings. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice, but a full registration statement.
2012-05-11 English
S-8 POS
Transaction in Own Shares Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Form S-8 Registration Statement filed with the SEC. Form S-8 is used for registering securities to be offered under employee benefit plans, specifically equity compensation plans. The document discusses registration of shares under equity compensation plans, amendments to these plans, and related registration fee calculations. It is a regulatory filing related to securities registration and equity compensation plans, not a financial report, earnings release, or other report types. The document is lengthy (15,000 characters) and contains detailed regulatory and legal information about the registration statement amendment. Therefore, the appropriate classification is Transaction in Own Shares (POS), which covers share repurchase/issuance and related filings such as Form S-8 amendments.
2012-05-11 English
FORM 10-Q
Interim / Quarterly Report Q1 2012
2012-05-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2012-04-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2012-04-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2012-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.